Company news

Ocugen, Inc. news in 2025

Ocugen, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

December 9, 2025

Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference

November 19, 2025

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

November 4, 2025

Ocugen to Host Webcast on Wednesday, November 5 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

October 22, 2025

Ocugen to Present at Industry and Investor Conferences in October 2025

October 1, 2025

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

September 14, 2025

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

September 1, 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

August 12, 2025

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

August 11, 2025

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

August 7, 2025

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

July 31, 2025

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

July 20, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

July 17, 2025

Ocugen to Host Conference Call on Friday, August 1 at 8: 30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

July 16, 2025

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

June 22, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

June 15, 2025

Ocugen To Present at BIO International Convention 2025

June 10, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

June 4, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 26, 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 8, 2025

Ocugen to Host Conference Call on Friday, May 9 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 1, 2025

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

April 28, 2025

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

April 7, 2025

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

March 17, 2025

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

March 2, 2025

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

February 26, 2025

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8: 30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

February 20, 2025

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

February 11, 2025

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

February 2, 2025

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

January 26, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

January 15, 2025

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

January 12, 2025

Calls in 2025

Decks in 2025